OSAM
NBIX icon

O'Shaughnessy Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$951K Buy
5,643
+679
+14% +$101K ﹤0.01% 1281
2026
Q1 		$654K Sell
4,964
-177
-3% -$23.5K ﹤0.01% 1398
2025
Q4 		$729K Buy
5,141
+546
+12% +$79.1K ﹤0.01% 1303
2025
Q3 		$645K Sell
4,595
-234
-5% -$31.7K ﹤0.01% 1361
2025
Q2 		$607K Buy
4,829
+1,599
+50% +$183K ﹤0.01% 1281
2025
Q1 		$357K Sell
3,230
-543
-14% -$68.8K ﹤0.01% 1482
2024
Q4 		$515K Sell
3,773
-36
-0.9% -$4.45K ﹤0.01% 1272
2024
Q3 		$444K Sell
3,809
-461
-11% -$63.2K ﹤0.01% 1285
2024
Q2 		$588K Buy
4,270
+575
+16% +$78.9K 0.01% 1063
2024
Q1 		$510K Buy
3,695
+531
+17% +$72.5K 0.01% 1093
2023
Q4 		$417K Buy
3,164
+109
+4% +$12.5K 0.01% 1084
2023
Q3 		$344K Buy
+3,055
New +$322K 0.01% 1054
2023
Q2 		– Sell
-2,366
Closed -$239K – 1553
2023
Q1 		$239K Sell
2,366
-543
-19% -$56.5K ﹤0.01% 1142
2022
Q4 		$347K Buy
2,909
+365
+14% +$42.8K 0.01% 917
2022
Q3 		$270K Buy
+2,544
New +$258K 0.01% 976
2021
Q4 		– Sell
-1,224
Closed -$118K – 2018
2021
Q3 		$118K Sell
1,224
-1,077
-47% -$102K ﹤0.01% 1304
2021
Q2 		$224K Buy
2,301
+37
+2% +$3.55K ﹤0.01% 973
2021
Q1 		$220K Sell
2,264
-259
-10% -$27.2K ﹤0.01% 891
2020
Q4 		$242K Buy
2,523
+738
+41% +$71.3K 0.01% 765
2020
Q3 		$172K Buy
1,785
+570
+47% +$65.9K 0.01% 747
2020
Q2 		$148K Buy
+1,215
New +$134K ﹤0.01% 740
2020
Q1 		– Sell
-23
Closed -$2K – 1618
2019
Q4 		$2K Buy
+23
New +$2.41K ﹤0.01% 1664

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

O'Shaughnessy Asset Management's NBIX Position: Q2 2026 in Review

O'Shaughnessy Asset Management increased its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, buying an estimated $101K and bringing the position to 5,643 shares worth $951K. The position accounts for ﹤0.01% of the portfolio, ranked #1281.

O'Shaughnessy Asset Management first reported a position in NBIX in Q4 2019 and has held it in 22 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • O'Shaughnessy Asset Management held 5,643 shares of Neurocrine Biosciences worth $951K as of Q2 2026.
  • O'Shaughnessy Asset Management bought 679 Neurocrine Biosciences shares in Q2 2026, an estimated $101K.
  • Neurocrine Biosciences made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1281 holding.
  • O'Shaughnessy Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 22 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.